Advanced search
Publication Cover
Current Eye Research Volume 36, 2011 - Issue 9
Submit an article Journal homepage
699
Views
49
CrossRef citations to date
0
Altmetric
Original Article

A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension

Ronald A. SchacharPfizer Inc, San Diego, California, USA and Meeting presentations: Research presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, May 2–6, 2010, Fort Lauderdale, Florida and at the Annual Meeting of the American Academy of Ophthalmology, October 16–19, 2010, Chicago, Illinois.Correspondence[email protected]
,
Susan RaberPfizer Inc, San Diego, California, USA and Meeting presentations: Research presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, May 2–6, 2010, Fort Lauderdale, Florida and at the Annual Meeting of the American Academy of Ophthalmology, October 16–19, 2010, Chicago, Illinois.
,
Rachel CourtneyPfizer Inc, San Diego, California, USA and Meeting presentations: Research presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, May 2–6, 2010, Fort Lauderdale, Florida and at the Annual Meeting of the American Academy of Ophthalmology, October 16–19, 2010, Chicago, Illinois.
&
Min ZhangPfizer Inc, San Diego, California, USA and Meeting presentations: Research presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, May 2–6, 2010, Fort Lauderdale, Florida and at the Annual Meeting of the American Academy of Ophthalmology, October 16–19, 2010, Chicago, Illinois.
Pages 809-817 | Received 09 Nov 2010, Accepted 29 May 2011, Published online: 18 Aug 2011

Citations (49)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Masato Matsuo, Yotaro Matsuoka & Masaki Tanito. (2022) Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension. Clinical Ophthalmology 16, pages 1261-1279.
Read now
Tyler M. Kaplan & Arthur J. Sit. (2022) Emerging drugs for the treatment of glaucoma: a review of phase II & III trials. Expert Opinion on Emerging Drugs 27:3, pages 321-331.
Read now
Andreas Katsanos, Ivano Riva, Banu Bozkurt, Gábor Holló, Luciano Quaranta, Francesco Oddone, Murat Irkec, Gordon N. Dutton & Anastasios G. Konstas. (2022) A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Expert Opinion on Drug Safety 21:4, pages 525-539.
Read now
Artemis Matsou & Eleftherios Anastasopoulos. (2018) Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma. Expert Opinion on Investigational Drugs 27:10, pages 777-785.
Read now
Daniel Flesch, Daniel Merk, Christina Lamers & Manfred Schubert-Zsilavecz. (2013) Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012). Expert Opinion on Therapeutic Patents 23:2, pages 233-267.
Read now

Articles from other publishers (44)

Isabell Kaczmarek, Isabel Wower, Katja Ettig, Christina Katharina Kuhn, Robert Kraft, Kathrin Landgraf, Antje Körner, Torsten Schöneberg, Susanne Horn & Doreen Thor. (2023) Identifying G protein-coupled receptors involved in adipose tissue function using the innovative RNA-seq database FATTLAS. iScience 26:10, pages 107841.
Crossref
Thota Ganesh. (2023) Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis. Journal of Medicinal Chemistry 66:14, pages 9313-9324.
Crossref
Najam A. Sharif. (2023) Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients. Pharmaceuticals 16:6, pages 791.
Crossref
S Subbulakshmi, Srinivasan Kavitha & Rengaraj Venkatesh. (2023) Prostaglandin analogs in ophthalmology. Indian Journal of Ophthalmology 71:5, pages 1768-1776.
Crossref
Seung Hyeun Lee, Won Jun Lee, Kyoung Woo Kim, Jae Hoon Jeong, In Ki Park & Yeoun Sook Chun. (2023) Influence of 0.002% Omidenepag Isopropyl on Intraocular Pressure and the Cornea in Normal Tension Glaucoma. Journal of Glaucoma 32:4, pages 245-251.
Crossref
Najam A. Sharif, Noriko Odani-Kawabata, Fenghe Lu & Leonard Pinchuk. (2023) FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma. Experimental Eye Research 229, pages 109415.
Crossref
Dominik Cebulla, Chiel van Geffen & Saeed Kolahian. (2023) The role of PGE2 and EP receptors on lung's immune and structural cells; possibilities for future asthma therapy. Pharmacology & Therapeutics 241, pages 108313.
Crossref
Hugo Garcia, Alice S. Serafin, Flora Silbermann, Esther Porée, Amandine Viau, Clémentine Mahaut, Katy Billot, Éléonore Birgy, Meriem Garfa-Traore, Stéphanie Roy, Salomé Ceccarelli, Manon Mehraz, Pamela C. Rodriguez, Bérangère Deleglise, Laetitia Furio, Fabienne Jabot-Hanin, Nicolas Cagnard, Elaine Del Nery, Marc Fila, Soraya Sin-Monnot, Corinne Antignac, Stanislas Lyonnet, Pauline Krug, Rémi Salomon, Jean-Philippe Annereau, Alexandre Benmerah, Marion Delous, Luis Briseño-Roa & Sophie Saunier. (2022) Agonists of prostaglandin E 2 receptors as potential first in class treatment for nephronophthisis and related ciliopathies . Proceedings of the National Academy of Sciences 119:18.
Crossref
Toru Nakazawa, Kanji Takahashi, Yasuaki Kuwayama, Akio Nomura & Fumiki Shimada. (2022) Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan. Advances in Therapy 39:3, pages 1359-1374.
Crossref
Reiko Yamagishi-Kimura, Megumi Honjo & Makoto Aihara. (2022) The Roles Played by FP/EP3 Receptors During Pressure-lowering in Mouse Eyes Mediated by a Dual FP/EP3 Receptor Agonist. Investigative Opthalmology & Visual Science 63:2, pages 24.
Crossref
Yosuke Ida, Araya Umetsu, Masato Furuhashi, Megumi Watanabe, Fumihito Hikage & Hiroshi Ohguro. (2021) The EP2 agonist, omidenepag, alters the physical stiffness of 3D spheroids prepared from human corneal stroma fibroblasts differently depending on the osmotic pressure. The FASEB Journal 36:1.
Crossref
Xianbo Wu, Xinwei Yang, Qi Liang, Xiali Xue, Jianli Huang, Jie Wang, Yihua Xu, Rongsheng Tong, Maoyu Liu, Qiaodan Zhou & Jianyou Shi. (2021) Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research. European Journal of Medicinal Chemistry 226, pages 113842.
Crossref
Makoto Aihara. (2021) Prostanoid receptor agonists for glaucoma treatment. Japanese Journal of Ophthalmology 65:5, pages 581-590.
Crossref
Donald J. AbrahamLiudmila L. Mazaleuskaya & Emanuela Ricciotti. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 1 54 .
Changxiu Qu, Chunyou MaoPeng XiaoQingya Shen, Ya-Ni ZhongFan YangDan-Dan Shen, Xiaona TaoHuibing Zhang, Xu YanRu-Jia ZhaoJunyan HeYing GuanChao ZhangGuihua HouPeng-Ju ZhangGuige Hou, Zijian LiXiao YuRen-Jie Chai, You-Fei GuanJin-Peng Sun & Yan Zhang. (2021) Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E 2 receptor EP2 subtype . Science Advances 7:14.
Crossref
Martin J. Lohse & Franz Grehn. 2021. Arzneiverordnungs-Report 2021. Arzneiverordnungs-Report 2021 639 666 .
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Noriko Odani-Kawabata & Naveed K. Shams. (2020) Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension. American Journal of Ophthalmology 220, pages 53-63.
Crossref
Yosuke Ida, Fumihito Hikage, Araya Umetsu, Haruka Ida & Hiroshi Ohguro. (2020) Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells. Scientific Reports 10:1.
Crossref
Martin J. Lohse. 2020. Arzneiverordnungs-Report 2020. Arzneiverordnungs-Report 2020 733 758 .
Liudmila L. Mazaleuskaya & Emanuela Ricciotti. 2020. Druggable Lipid Signaling Pathways. Druggable Lipid Signaling Pathways 29 54 .
Christopher M. Adams & Julien P. N. Papillon. 2020. Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases. Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases 189 256 .
Makoto AiharaFenghe LuHisashi KawataYuki TanakaKenzo YamamuraNoriko Odani-KawabataNaveed K. Shams. (2019) Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study). Journal of Ocular Pharmacology and Therapeutics 35:10, pages 542-550.
Crossref
David F. WoodwardJenny W. WangW. Daniel StamerE. Lütjen-DrecollAchim H.-P. KraussCarol B. Toris. (2019) Antiglaucoma EP 2 Agonists: A Long Road That Led Somewhere . Journal of Ocular Pharmacology and Therapeutics 35:9, pages 469-474.
Crossref
David F. WoodwardJenny W. WangRobert A. ColemanAmanda J. WoodrooffeKenneth L. ClarkW. Daniel StamerGuoxian TaoShan FanCarol B. Toris. (2019) A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method. Journal of Ocular Pharmacology and Therapeutics 35:5, pages 265-277.
Crossref
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Kathy Liu, Noriko Odani-Kawabata & Naveed K. Shams. (2019) Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. Journal of Glaucoma 28:5, pages 375-385.
Crossref
Francesco Impagnatiello, Elena Bastia, Nicoletta Almirante, Stefania Brambilla, Brigitte Duquesroix, Angela C Kothe & Michael V W Bergamini. (2018) Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. British Journal of Pharmacology 176:8, pages 1079-1089.
Crossref
R A Coleman, A J Woodrooffe, K L Clark, C B Toris, S Fan, J W Wang & D F Woodward. (2019) The affinity, intrinsic activity and selectivity of a structurally novel EP 2 receptor agonist at human prostanoid receptors . British Journal of Pharmacology 176:5, pages 687-698.
Crossref
Martin J. Lohse. 2019. Arzneiverordnungs-Report 2019. Arzneiverordnungs-Report 2019 877 902 .
Martin J. Lohse. 2018. Arzneiverordnungs-Report 2018. Arzneiverordnungs-Report 2018 693 714 .
Tijana Markovič, Žiga Jakopin, Marija Sollner Dolenc & Irena Mlinarič-Raščan. (2017) Structural features of subtype-selective EP receptor modulators. Drug Discovery Today 22:1, pages 57-71.
Crossref
Martin J. Lohse. 2017. Arzneiverordnungs-Report 2017. Arzneiverordnungs-Report 2017 641 661 .
Georges Kalouche, Céline Boucher, Annick Coste, Laurent Debussche, Cécile Orsini, Christophe Baudouin, Thomas Debeir, Xavier Vigé & William Rostène. (2016) Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1863:9, pages 2322-2332.
Crossref
Martin J. Lohse. 2016. Arzneiverordnungs-Report 2016. Arzneiverordnungs-Report 2016 621 641 .
Rajinder K. Bhardwaj. 2016. Pharmacology of Ocular Therapeutics. Pharmacology of Ocular Therapeutics 13 35 .
Carol A. Rasmussen & Paul L. Kaufman. (2014) Exciting directions in glaucoma. Canadian Journal of Ophthalmology 49:6, pages 534-543.
Crossref
Thota Ganesh, Jianxiong Jiang & Ray Dingledine. (2014) Development of second generation EP2 antagonists with high selectivity. European Journal of Medicinal Chemistry 82, pages 521-535.
Crossref
Thota Ganesh. (2013) Prostanoid Receptor EP2 as a Therapeutic Target. Journal of Medicinal Chemistry 57:11, pages 4454-4465.
Crossref
Gina M. YanochkoTimothy AffolterJohnnie J. EighmyMark G. EvansSu Khoh-ReiterDong LeePaul E. MillerMichael H. I. ShiueDusko TrajkovicBart A. Jessen. (2014) Investigation of Ocular Events Associated with Taprenepag Isopropyl, a Topical EP2 Agonist in Development for Treatment of Glaucoma. Journal of Ocular Pharmacology and Therapeutics 30:5, pages 429-439.
Crossref
Martin J. Lohse. 2014. Arzneiverordnungs- Report 2014. Arzneiverordnungs- Report 2014 861 890 .
Ronald A. Schachar, Susan Raber, Kristina V. Thomas, Beth Ann M. Benetz, Loretta B. Szczotka-Flynn, Min Zhang, Scott J. Howell & Jonathan H. Lass. (2013) Subclinical Increased Anterior Stromal Reflectivity With Topical Taprenepag Isopropyl. Cornea 32:3, pages 306-312.
Crossref
Claudio Bucolo, Salvatore Salomone, Filippo Drago, Michele Reibaldi, Antonio Longo & Maurizio Giacinto Uva. (2013) Pharmacological management of ocular hypertension: current approaches and future prospective. Current Opinion in Pharmacology 13:1, pages 50-55.
Crossref
Martin J. Lohse. 2013. Arzneiverordnungs-Report 2013. Arzneiverordnungs-Report 2013 765 792 .
Kang Zhang, Liangfang Zhang & Robert N. Weinreb. (2012) Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nature Reviews Drug Discovery 11:7, pages 541-559.
Crossref
Ulrich Schwabe & Dieter PaffrathMartin J. Lohse. 2012. Arzneiverordnungs-Report 2012. Arzneiverordnungs-Report 2012 775 801 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.